Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva. 

Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.

Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.